BioTech AEON 5 Biotech Stocks In Spotlight: Tenon Medical, AEON Biopharma, Silexion, Orchestra BioMed & Indaptus September 10, 2026 — 02:49 pm EDT Written by RTTNews.com for RTTNews linkedin facebook x email reddit (RTTNews) - Several biotech stocks were in focus Thursday, including Tenon Medical following the full repayment of its senior convertible promissory notes; AEON Biopharma after positive forced degradation study results for ABP-450; Silexion Therapeutics ahead of several September investor conferences; Orchestra BioMed following an upcoming investor conference presentation; and Indaptus Therapeutics after reporting second-quarter results and providing a corporate update. Read on… Tenon Medical ( TNON ) fully repaid its outstanding senior convertible promissory notes, with an aggregate principal balance of approximately $5.16 million, ahead of their September 11, 2026 maturity date. The repayment is expected to strengthen the company's balance sheet and eliminate potential dilution from conversion of the notes into common stock. Tenon has developed the Catamaran SI Joint Fusion System, a less invasive SI joint fusion device using a single titanium implant. Currently, TNON is trading at $4.30, up 76.96%. AEON Biopharma ( AEON ) announced positive results from a pilot forced degradation study comparing ABP-450 with BOTOX, providing additional analytical evidence supporting comparability between the two products. Under thermal stress, both products showed comparable potency loss, while oxidative stress testing showed similar dose-dependent oxidation patterns. ABP-450 is a 900-kDa botulinum toxin type A complex being developed as a biosimilar to BOTOX through the FDA's 351(k) pathway. Currently, AEON is trading at $0.31, up 35.41%. Shares of Silexion Therapeutics ( SLXN ) are surging more than 14% on Thursday after the company announced that its management team will participate in several industry and investor conferences in September 2026. Chief Scientific and Development Officer Mitchell Shirvan is scheduled to present at two oncology and RAS-focused conferences, while CEO Ilan Hadar and CFO Mirit Horenshtein Hadar will hold one-on-one meetings at the H.C. Wainwright Global Investment Conference. Silexion is developing SIL204, an investigational pan-KRAS RNA interference therapy, in a Phase 2/3 program for locally advanced pancreatic cancer. Currently, SLXN is trading at $0.40, up 14.45%. Shares of Orchestra BioMed ( OBIO ) are surging more than 10% on Thursday, with the stock posting a notable gain in pre-market trading. The company recently announced that Chairman and CEO David Hochman will participate in the H.C. Wainwright 28th Annual Global Investment Conference on September 16, 2026, where he will deliver a presentation and hold one-on-one meetings with investors. Orchestra BioMed is advancing AVIM Therapy for uncontrolled hypertension and Virtue SAB for atherosclerotic artery disease, with its pivotal BACKBEAT Trial on track to reach 284 evaluable patients by the end of the third quarter of 2026. Currently, OBIO is trading at $5.96, up 11.16%. Shares of Indaptus Therapeutics ( INDP ) are surging more than 20% on Thursday, with the stock posting a sharp gain in pre-market trading. The company recently reported second-quarter 2026 results, highlighting a strengthened balance sheet following a $12.0 million private placement and its ongoing review of strategic alternatives. Indaptus is evaluating its Decoy20 program and broader operations while exploring research collaborations, strategic investments, acquisitions and potential business combinations. The company also began a research collaboration focused on neurological disorders and sleep. Currently, INDP is trading at $2.51, up 20.61%. Did you know? September 17 is World Patient Safety Day. In 2026, WHO is focusing on safe care for people living with noncommunicable diseases, which include cardiovascular diseases, cancers, diabetes and chronic respiratory diseases. RTTNews Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges. More articles by this source facebook x website Tags BioTech Stocks Mentioned AEON INDP OBIO SLXN TNON Latest Articles Data is currently not available